

# Generic Drugs & Promise of Regulatory Science

(3/3)



**Obaid Ali & Roohi B. Obaid**

April 08<sup>th</sup>, 2015

Hotel Regent Plaza, Karachi







All Praise be to  
ALLAH





# Generic Drugs

## Promise of Regulatory Science

### Session 4

## Emerging Challenges & Radar Navigation

Obaid Ali, Roohi B. Obaid







# Generic-A Great Claim

A generic drug is the same as brand name drug

In Dosage

The way it is taken

The way it  
should be  
used

In Safety

The way it works

In Strength

In Quality





# Generic- Perception or Reality

Our drugs are equal quality

Give me Tylenol instead of Panadol

We do not compromise on quality  
and put in 100% API

More than 50% drugs are fake

We & our kids use the same drugs,  
we manufacture





# Great Challenge with Generics


1 Manufacturing  
& Quality  
Control

2 Product  
Characteristic &  
Label

3 Therapeutic  
Equivalency

80%

125%



# Dosage Form Change Over ???



Reference drug is  
in tablet form

- Can we manufacture injection instead of tablet?



Let's think

- Is there need of any clinical study to go for injection?

Do you think

- Has clinical studies nothing to do with dosage form?



Open for discussion. If you have any reference of any developed country, it will be added knowledge.





# Overage

Ergotamine  
Tartarate

Thyroxine

ACE  
Inhibitors

Tobramycin





# Overage

Generally, use of overage is discouraged. An overage in the drug product, whether it appears in the final product or not, should be **JUSTIFIED** considering the safety and efficacy of the product. Important aspects are

Amount of  
overage

Reason of  
overage

Justification  
for the amount  
of overage





# Stability

Caraco Pharmaceuticals, a  
subsidiary of Sun Pharma

Venlafaxine HCl ER tabs

Failed in dissolution

Stability results went out





# Dissolution Failure



Metoprolol Succinate Tabs ER  
Recall due to dissolution

2009 Ethex (KV  
Pharmaceuticals)  
2014 Wockhardt & Ranbaxy



Tropol XL (Sandoz) approved  
in 1992

Recalled due to dissolution



Therapeutic failure reported in  
2007

What do you think?

Formulation had not been  
properly validated (FDA 2008)

What should we learn?





# Sometimes Maths does not favor



## ADHD

- Mallinckrodt
- Methyl Phenidate HCl tab
- 18, 27, 36, 54 mg dose

## Failure

- Fasting & fed had two different behavior in extended release





# Sometimes Maths does not favor



## Bupripion HCl tab

- Study on low dose and waiver on high dose



## Failure

- Desired kinetics was not achieved



## Teva

- FDA asked to stop distribution in sep 2012





# Sometimes Maths does not favor

Bupripion (Wellbutrin) IR  
Tab of SKB 1985

Bupripion SR Tab 1996  
& XL Tab 2003

Based on evidence  
demonstrating BE with low  
strength

In 2006, Generic version  
Mfg by Impax/Teva were  
approved

85 post marketing reports  
from Jan-Jun 2007

Experienced undesirable  
effects

Increased side effects,  
Decreased therapeutic effect

Re-switched on brand

B  
U  
P  
R  
I  
P  
I  
O  
N





# Sometimes Maths does not favor

Temporal relationship  
under question

FDA re-examined BE  
data

Conducted study

Withdrawal of Teva drug  
in Mar 2013 against Sep  
2012 FDA advice

B  
U  
P  
R  
I  
P  
I  
O  
N

Also generic of Actavis  
withdraw their version

A new challenge

General rule will not  
work always

Its life, please care





# Production Scale up



- Apotex Canada
- HTZ capsule 12.5 mg failed upon scale up in assay.




- Failure was limited to some batches
- Root cause was not identified even after a year.





# Tablet Scoring




Scoring is not a cosmetic issue  
but important .....






# Supplier Qualification





# Supplier Qualification



Can a drug product manufactured from a non-compliant API ensure safety???





# Analytical Method

